We are building a novel therapeutic approach for cancer of unknown primary — a disease that has seen virtually no progress in decades.
Our platform does not require identification of the primary tumour site. We exploit biology that is conserved regardless of tissue-of-origin.
No biotech or pharma company in the world has CUP as its primary disease focus. We are building the first dedicated therapeutic platform.
A mechanistic hypothesis that addresses the ~68% of CUP patients left behind by current molecular profiling approaches.
We're building Phantom Therapeutics to change the outlook for CUP patients worldwide.
Get in Touch